SUMMARY OF INVERVIEW

Identification of Claims Discussed

All pending claims were discussed.

Principal Arguments and Other Matters

Applicants' representative discussed the pending Office Action and the issues raised by the Examiner with respect to the enablement and written description rejections. Applicants' representative proposed directing the claims to an 8 nucleobase portion of SEQ ID NO: 23, and deleting references to plasminogen. Applicants' representative additionally proposed amending claim 30 to add a step of selecting a human having elevated plasma lipoprotein(a) levels.

Results of Interview

The Examiners indicated that the proposed claim amendments would be looked upon favorably. It was decided that Applicants do not need to specify a mode of administration to overcome the pending enablement rejection related to modes of administration.